Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.
Journal Article (Journal Article)
Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10-20% of patients. Here we perform genomic analysis of tumor tissue from recurrent WHO grade IV glioblastoma patients acquired prior to immunotherapy intervention. We report that very low tumor mutation burden is associated with longer survival after recombinant polio virotherapy or after immune checkpoint blockade in recurrent glioblastoma patients. A relationship between tumor mutation burden and survival is not observed in cohorts of immunotherapy naïve newly diagnosed or recurrent glioblastoma patients. Transcriptomic analyses reveal an inverse relationship between tumor mutation burden and enrichment of inflammatory gene signatures in cohorts of recurrent, but not newly diagnosed glioblastoma tumors, implying that a relationship between tumor mutation burden and tumor-intrinsic inflammation evolves upon recurrence.
Full Text
- Published version (via Digital Object Identifier)
- Pubmed Central version
- Open Access Copy from Duke
- Link to Item
Duke Authors
- Ashley, David Michael
- Bigner, Darell Doty
- Bolognesi, Dani Paul
- Brown, Michael
- Desjardins, Annick
- Friedman, Allan Howard
- Friedman, Henry Seth
- Gromeier, Matthias
- He, Yiping
- Herndon II, James Emmett
- Khasraw, Mustafa
- McLendon, Roger Edwin
- Nair, Smita K
- Peters, Katherine Barnett
- Sampson, John Howard
- Yan, Hai
Cited Authors
- Gromeier, M; Brown, MC; Zhang, G; Lin, X; Chen, Y; Wei, Z; Beaubier, N; Yan, H; He, Y; Desjardins, A; Herndon, JE; Varn, FS; Verhaak, RG; Zhao, J; Bolognesi, DP; Friedman, AH; Friedman, HS; McSherry, F; Muscat, AM; Lipp, ES; Nair, SK; Khasraw, M; Peters, KB; Randazzo, D; Sampson, JH; McLendon, RE; Bigner, DD; Ashley, DM
Published Date
- January 13, 2021
Published In
Volume / Issue
- 12 / 1
Start / End Page
- 352 -
PubMed ID
- 33441554
Pubmed Central ID
- PMC7806846
Electronic International Standard Serial Number (EISSN)
- 2041-1723
Digital Object Identifier (DOI)
- 10.1038/s41467-020-20469-6
Language
- eng
Conference Location
- England